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In patients with alcoholic cardiomyopathy there is evidence
that mild heart failure is reversible if patients abstain from
alcohol, but there is no consensus whether the disease is
progressive once structural myocardial dilatation has
evolved. The aim of the present study was to compare the
long-term course of congestive heart failure due to alcoholic
and idiopathic dilated cardiomyopathy.
Of 75 patients with overt congestive heart failure, 23
had alcoholic cardiomyopathy and were compared to 52
patients with idiopathic cardiomyopathy. The mean age
was 48 ± 12 years. Despite medical therapy, heart failure
class New York Heart Association III—IV was present in
52% of patients with alcoholic and 47% of patients with
idiopathic cardiomyopathy (not significant). Their mean
left ventricular ejection fraction was 30 ± 12% vs 28 ± 12%
and left ventricular end-diastolic volumes were 264 ±
125 ml and 254 ± 100 ml respectively (not significant).
Overall survival at 1, 5 and 10 years was 100%, 81% and
81% for the group with alcoholic dilated cardiomyopathy
and 89%, 48% and 30% for the group with idiopathic
cardiomyopathy, respectively (P=0041), and the difference
was even greater for transplant-free survival P=0-005).
Clinical and invasive signs of left and right heart failure as
well as left ventricular dimensions were predictive of a fatal
outcome; however, symptom duration and left ventricular
volumes were only predictive in patients with idiopathic
cardiomyopathy, suggesting that in the two patient groups
different mechanisms may lead to death.
Mortality in patients with severe congestive heart failure
and left ventricular dilatation due to alcoholic cardio-
myopathy is significantly lower than that in patients with
idiopathic cardiomyopathy and similar degrees of heart
failure. Thus, despite structural changes inherent in marked
left ventricular dilatation, disease progression in alcoholic
dilated cardiomyopathy is different from that in idiopathic
cardiomyopathy and thus may have implications for the
choice of therapy.
(Eur Heart J 1996; 17: 251-257)
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Introduction
The natural history of idiopathic cardiomyopathy has
been described by several authors, with 5-year survival
rates ranging between 65% and 25%l'"6]. It has recently
been recognized that referral bias affects the apparent
natural history of idiopathic dilated cardiomyopathy
and that survival in referral patients with this disease is
significantly better than previously described'71. Heart
transplantation, a therapeutic option for end-stage
congestive heart failure, is usually withheld in patients
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whose cardiomyopathy has an alcoholic aetiology.
Instead the treatment of choice is abstinence from alco-
holic beverages as well as medical therapy with diuretics,
ACE inhibitors and digitalis. Alcohol withdrawal may
have remarkable short-term effects, especially in milder
forms of the disease18"101, but this may not be the case in
patients with left ventricular dilatation due to structural
changes1"1. In addition, it is well recognized that many
patients will not remain abstinent even after their first
left heart decompensation'121. Despite a relatively large
number of such patients in Europe, there is almost no
long-term data available describing the natural history
and outcome of their disease.
The aim of the present study was, therefore, to
investigate the long-term outcome of patients with signs
and symptoms of overt heart failure due to alcoholic
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dilated cardiomyopathy and to compare it to that of
patients with similar degrees of congestive heart failure
due to idiopathic cardiomyopathy.
Methods
Patients
In a retrospective analysis, all patients referred to our
hospital for invasive evaluation of overt congestive heart
failure between 1981 and 1992 were screened. Patients
were excluded from this analysis if they had a left
ventricular ejection fraction >50% or if a cause other
than alcohol abuse could be identified as being respon-
sible for their disease (i.e. coronary artery disease,
hypertensive heart disease or history of hypertension,
valvular or congenital heart disease, thyrotoxic heart
disease, diabetes mellitus). The remaining 75 patients
fulfilled the inclusion criteria and formed the study
population for the present analysis. In 23 of them (31%)
an alcoholic aetiology of their heart disease could be
identified based on their history, clinical examination
and laboratory findings. All of these patients had been
drinking at least 80 g of ethanol per day over a period
of at least 5 years. In the remaining 52 patients (69%)
no specific aetiology could be found and they were
considered to suffer from idiopathic cardiomyopathy.
Clinical evaluation
All patients were clinically examined and followed by
experienced cardiologists. The initial evaluation in-
cluded a 12-lead electrocardiogram, chest X-ray and left
heart catheterization by the Judkins technique in all
patients. For most of them, additional data from other
investigations such as right heart catheterization (n=46)
and echocardiography (n = 50) were available for analy-
sis. Patients were regularly followed in our outpatient
clinic or by their private cardiologists. Final follow-up
information was obtained from the patients directly or
from their private physicians. Deaths were verified
through hospital records, autopsy reports and death
certificates where necessary. All-cause mortality was
used as sole end-point. In order to account for a survival
benefit due to heart transplantation in patients with
end-stage heart failure, transplant-free survival was also
assessed.
Statistics
All values are presented as mean ± one standard devia-
tion. Comparison between groups were done using the
two-tailed Student's t-test for unpaired samples and the
Chi-square test for proportions. Actuarial life table
analysis was calculated based on the method described
by Kaplan-Meier"31. Survival was calculated as overall
survival and transplant free survival. A /'-value of <005
was considered to indicate a significant difference.
Table 1 Clinical findings at the time of diagnosis
Age (years)
Duration of symptoms (months)
Dyspnoea
NYHA class I—11 (%)
NYHA class III—IV (%)
Syncope (%)
Chest pain (%)
Atrial fibrillation (%)
Third heart sound (%)
Positive hepato-jugular reflux (%)
Heart size (cm)
Cardiothoracic ratio
IDCM
49 ± 15
19 ±29
53
47
23
55
21
45
18
17-7 ±2-2
0-55 ± 006
ADCM
47 ± 8
20 ±22
48
52
17
61
22
52
22
16 9 ± 2 0
0-51 ±0-05
ADCM = alcoholic dilated cardiomyopathy; mean values ± one
standard deviation are given; IDCM = idiopathic dilated cardiomy-
opathy; NYHA class=New York Heart Association functional
classes: 1 — asymptomatic, II — symptoms during strong exercise,
III — symptoms during mild exercise, IV — symptoms at rest.
There were no statistically significant differences.
Results
Clinical parameters
Patient characteristics are described in Table 1. All
patients were referred for management of congestive
heart failure and presented with symptoms lasting for an
average of 21 to 24 months before inclusion in the study.
Symptoms were shortness of breath (47-52% in New
York Heart Association class III—IV despite medical
therapy), atypical chest pain and syncope. In 49% of
the patients the resting heart rate was elevated to above
90 beats per minute and a third heart sound was present
in 47% of the patients. Atrial fibrillation was docu-
mented in 21% and 22% respectively. Standard chest
X-ray documented a heart size ^ 15-5 cm in 83% of
patients. Sixty-eight percent of patients were on diuretics
and 45% on digoxin; ACE inhibitors were only avail-
able in the latter part of the study, where it became
standard treatment. As indicated in Table 1, there were
no significant differences in any of these parameters
between patients with alcoholic and idiopathic
cardiomyopathy, respectively.
Haemodynamic and laboratory
measurements
Haemodynamic and laboratory data are given in Tables
2 and 3. The stroke volume index was 31 ± 13 ml. m~2
in patients with idiopathic cardiomyopathy and
28 ± 11 ml. m ~2 in patients with alcoholic dilated
cardiomyopathy, respectively {P not significant). Left
ventricular ejection fraction and left as well as right sided
filling pressures and volumes were markedly increased
(end-diastolic volumes: 254 ± 100 ml for idiopathic car-
diomyopathy and 264 ± 124 ml for alcoholic dilated
Eur Heart J. Vol. 17, February 1996
Disease progression in CHF 253
Table 2 Haemodynamic data at the time of diagnosis
Heart rate (beats . min ')
Systolic blood pressure (mmHg)
Diastolic blood pressure (mmHg)
Stroke volume index (ml. m ~ *)
PAP mean (mmHg)
CVP (mmHg)
PCW (mmHg)
LVEF (%)
LVEDV (ml)
LVEDP (mmHg)
IDCM
89 ± 16
121 ±16
80 ± 10
31 ± 13
28 ±10
9 ± 5
21 ± 8
28 ±12
254 ±100
20 ± 9
ADCM
95 ± 16
125±18
81 ± 10
28 ± 11
23 ± 10
8 ± 3
17 ± 8
30 ± 12
264±125
20 ± 9
CVP=central venous pressure; LVEDP=left ventricular end-
diastolic pressure; LVEDV = left ventricular end-diastolic volume;
LVEF=left ventricular ejection fraction; PAP=pulmonary artery
pressure; PCW=pulmonary capillary wedge pressure There were
no statistically significant differences.
Table 3 Laboratory data at the time of diagnosis
Haemoglobin (g . dl ')
Leucocytes (10 9 . l" ' )
Platelet count ( l O ' . r 1 )
y G T ( < 6 0 U . r ' )
S G O T ( 6 - 2 5 U . r ' )
SGPT (3-36 U . I " ' )
Creatinine (71-120 umol. 1"')
IDCM
14-9 ± 1-6
81 ± 3 0
235 ± 69
73 ± 137
20± 11
27 ±20
100 ±45
ADCM
15-5 ± 1-5
8-9 ± 2 0
214±47
181 ±186
31 ±18
57 ±55
87± 18
P-value
ns
ns
ns
<0-05
<005
<001
ns
SGOT = aspartate aminotransferase; SGPT=alanine aminotrans-
ferase; yGT = gamma glutamyl transferase. Normal values are
referenced in parenthesis.
cardiomyopathy patients; P not significant). Hence,
there were no relevant differences in haemodynamic
measurements between the two study groups at baseline.
This was confirmed by echocardiographic measurements
in 50 patients; however, Doppler ultrasound demon-
strated the presence of mitral regurgitation in 69% of
idiopathic vs only 22% (P<005) in alcoholic patients.
There were no significant differences in laboratory par-
ameters, except for measurements of gamma glutamyl
transferase, aspartate aminotransferase and alanine
aminotransferase, which were significantly higher in
patients with alcoholic compared to patients with idio-
pathic cardiomyopathy (at least P<0-05), confirming
hepatic disease due to chronic alcohol intoxication.
Survival and predictors of death
Figure 1 shows the overall and transplant-free survival
for the whole study population over a 10-year period.
Overall mortality for the group as a whole was 7% at
one year and 43% at 5 years. A total of eight patients
with idiopathic cardiomyopathy but none with alcoholic
dilated cardiomyopathy underwent heart transplanta-
tion during the follow-up period (two at 2, two at 6
months and one at 8, 11,51 and 57 months of follow-up,
respectively).
The probability of survival was 81% at 10 years
in the group with alcoholic dilated cardiomyopathy
compared to 30% in the group with idiopathic cardio-
myopathy (P<005; Fig. 2). If transplant-free survival
was compared (Fig. 3) the difference between the two
groups was even greater, with transplant free survival
after 10 years of only 20% for idiopathic cardio-
myopathy as compared to 81% for alcoholic dilated
cardiomyopathy patients (P<0-01). Overall survival
after one year was 100% and 89% for the groups with
alcoholic dilated cardiomyopathy and idiopathic cardio-
myopathy, respectively; this decreased to 81% and 68%
after 2 years and to 81% and 48% after 5 years,
respectively.
Dyspnoea New York Heart Association class
III-rV, presence of a positive hepato-jugular reflux and
neck vein congestion as signs of biventricular heart
failure were the most important clinical predictors of
Table 4 Univariate positive predictors of fatal outcome in patients with idiopathic
(IDCM) and alcoholic dilated cardiomyopathy (ADCM)
Age (years)
Symptom duration (months)
Dyspnoea NYHA III-IV (%)
Neck vein congestion (%)
Hepato-jugular reflux (%)
Diuretics (%)
Digoxin (%)
LVEF (%)
LVEDV (ml)
LVESV (ml)
LVEDP (mmHg)
Alive
(n = 25)
51 ± 10
12 ± 13
16
8
0
64
36
34±9
208 ±50
131 ±35
16 ± 7
IDCM
Dead
(n = 27)
48 ± 15
35 ±35
52
46
35
93
70
23 ±11
300± 116
246 ± 120
24 ± 9
P
ns
<001
<001
<0-01
<0 01
<005
<005
<001
<001
<001
<001
Alive
(n = 20)
46±8
22 ±23
20
25
15
30
20
32 ±12
265±130
185 ± 113
19±9
ADCM
Dead
(n = 3)
47 ± 6
7 ± 5
100
67
67
100
67
15±6
250
203
21 ± 9
P
ns
ns
<001
ns
<005
<005
ns
ns
—
—
ns
Abbreviations as in Table 2. LVESV = left ventricular end-systolic volume.
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Figure 1 Overall survival (solid line) and transplant-free
survival (dotted line) in the study population. The survival
curves are shown for the whole study group comprising
23 patients with alcoholic and 52 patients with dilated
cardiomyopathy.
12 24 36 48 60 72 84 96 108 120
Time (months)
Figure 3 Transplant-free survival comparing patients
with idiopathic cardiomyopathy (dotted line) and alcoholic
dilated cardiomyopathy (solid line). Note, eight patients
with idiopathic cardiomyopathic underwent heart trans-
plantation during the 10-year follow-up, compared to none
of the patients with alcoholic dilated cardiomyopathy.
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Figure 2 Overall survival comparing patients with idio-
pathic cardiomyopathy (dotted line) and alcoholic dilated
cardiomyopathy (solid line).
death, whereas atrial fibrillation was not. These clinical
findings were substantiated by invasive measurements:
left ventricular ejection fraction and volumes as well as
left ventricular filling pressures were predictive of a fatal
outcome by univariate analysis; however, these results
were only significant in patients with idiopathic cardio-
myopathy and not in patients with alcoholic dilated
cardiomyopathy due to the low death rate in this latter
group. Age was not a predictor of death in these patients
and symptom duration was only predictive in idiopathic
cardiomyopathy patients.
depressed left ventricular ejection fraction and markedly
increased left ventricular volumes were indicative of
dilatative cardiomyopathy and documented invasively in
all patients. All patients required aggressive medical
treatment and eight with idiopathic cardiomyopathy
underwent heart transplantation. In contrast none of the
patients with alcoholic cardiomyopathy was trans-
planted. Overall survival over 10 years was significantly
better for patients with alcoholic dilated cardiomyo-
pathy than for those with idiopathic cardiomyopathy
and this difference was even greater for transplant-free
survival.
Patient selection
The characteristics of our patient population were
similar to those of previously published reports on
patients with congestive heart failure due to idiopathic
cardiomyopathy. The mean age of 48 years was rela-
tively low in the present study I8'14"16), but the duration
of symptoms at the time of presentation, the prevalence
of heart block and atrial fibrillation were comparable
to findings of others18-14-15'17"201. In contrast to other
reports, all of our patients underwent angiography com-
bined with left ventriculography, providing the advan-
tage that patients with silent coronary artery disease
were excluded from this study and an accurate measure-
ment of left ventricular function was obtained at the
same time.
Discussion
All patients in this study presented with clinical signs of
heart failure, which had lasted for an average of almost
2 years at the time they were included. Severely
Alcoholic cardiomyopathy
The diagnosis of alcoholic cardiomyopathy was based
on the diagnosis of idiopathic cardiomyopathy in
patients admitting regular consumption of large
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amounts of alcohol. The amount of daily alcohol intake
necessary to induce alcoholic cardiomyopathy varies
widely in individuals and there are also large variations
reported in the literature16'1112'21'221. In our patients the
admitted amount of alcohol intake was also very vari-
able, but all of them consumed at least 80 g alcohol per
day on a regular basis. In our series, myocardial biopsies
were performed in only four patients, resulting uni-
formly in non-specific findings; this is in accordance with
findings from other studies which found no specific
histopathological markers for idiopathic or alcoholic
cardiomyopathy1231. For the development of alcoholic
dilated cardiomyopathy, the level of liver and cardiac
enzyme activity appears to be of great importance, a
hypothesis which is confirmed by experiments with rats
in which this disease developed only when there was
simultaneous alcohol administration and inhibition of
catalase activity1241. In our study, alanine aminotrans-
ferase, aspartate aminotransferase and gamma glutamyl
transferase enzyme levels were markedly increased in
patients with alcoholic dilated cardiomyopathy as
compared to patients with idiopathic cardiomyopathy.
Richardson and co-workers noted that myocardial and
liver enzymes are increased in patients with alcoholic
dilated cardiomyopathy and correlate with the amount
of alcohol intake1251. Since alcoholic dilated cardio-
myopathy and liver disease are usually not associated,
these authors argued that their findings support the
concept of alcoholic heart muscle disease as a distinct
entity.
There is evidence from experimental'261 and
human19'101 studies that alcohol withdrawal may normal-
ize left ventricular dysfunction, at least in acute or early
stages of the disease. Whether this is true in patients
presenting with congestive heart failure and left and
right heart dilation with corresponding structural
changes'10'261 is not known. In fact, two studies18'271
reported improved survival in some patients abstaining
from alcohol, whereas another study showed no survival
benefit from alcohol abstinence in such patients'281. Even
in the study with improved survival after alcohol absten-
tion'81, the clinical cardiac status did not improve in most
patients.
Survival of patients with alcoholic
cardiomyopathy
In view of the difficulties in differentiating cardiac non-
sudden death due to heart failure from sudden death
in such patient groups'16'18', and considering the low
prevalence of sudden death due to alcoholism in young
and middle-aged persons'29', total mortality only is
reported in this study. Since it was intended to describe
the natural history of the disease, both overall and
transplant-free survival were analysed in order to correct
for the bias incurred by the survival benefit from heart
transplantation in the group with idiopathic cardio-
myopathy. The observed long-term survival of patients
with congestive heart failure due to idiopathic cardio-
myopathy was similar to that previously published'61.
Survival of patients with alcoholic dilated cardiomyo-
pathy, however, was significantly better, particularly if
transplant-free survival was compared. This contrasts
with another similarly large series reported it the litera-
ture161 where no difference in mortality was found. The
reasons remain speculative, but this difference could
partly be explained by more aggressive medical treat-
ment, firm advice to refrain from alcohol and the
enrollment of patients in supervised alcohol withdrawal
programmes whenever feasible; however, the effect of
this strategy, and particularly whether or not patients
remained abstinent, was not controlled in this retro-
spective study and remains subject to a prospective trial.
The comparatively low mortality rate observed in
patients with alcoholic dilated cardiomyopathy, severe
congestive heart failure and marked left ventricular
dilatation indicates that these patients may have
an unexpectedly good long-term course on medical
treatment and may, therefore, not qualify for heart
transplantation.
Predictors of death
Previous studies have identified shortness of breath,
age, underlying coronary artery disease, systolic blood
pressure and heart size as predictors of death in patients
with congestive heart failure due to idiopathic cardio-
myopathy'2-517'30"331. In contrast, there are controversial
reports about the prognostic impact of left ventricular
ejection fraction'15-16'2030'311, atrial fibrillation"'14'16'201
and ventricular dilatation'3'34"361 in these patients. The
present study did not intend to define such prognostic
predictors; however, our observations in patients with
idiopathic cardiomyopathy identified clinical findings of
overt biventricular heart failure, such as severe physical
limitation (dyspnoea New York Heart Association class
III-IV), congested neck veins and a positive hepato-
jugular reflux as predictors of a fatal outcome, which is
in accordance with previous studies. These clinical find-
ings were substantiated by invasive measurements of left
ventricular dysfunction and dilatation. However, these
latter parameters were only predictive in patients with
idiopathic but not in those with alcoholic dilated cardio-
myopathy. Although this difference may be due to the
smaller number of alcoholic dilated cardiomyopathy
patients, the low event rate in this group suggests a
different disease progression and thereby supports the
hypothesis that left ventricular dilatation has a different
prognostic importance in patients with alcoholic as
compared to idiopathic congestive cardiomyopathy.
Similarly, a longer duration of symptoms before diagno-
sis was predictive of death in patients with idiopathic
cardiomyopathy but not alcoholic dilated cardiomyo-
pathy, indicating that mechanisms other than long-
standing congestive heart failure might lead to death in
patients with alcoholic cardiomyopathy.
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Limitations of the study
The present study is a retrospective analysis based on a
population referred for work-up and management of
overt congestive heart failure. Since it was performed
retrospectively, the effect of medical therapy and docu-
mented alcohol abstinence on long-term survival and
disease progression could not be properly evaluated.
One very recent report on a very small subgroup of
seven patients suggested that alcohol abstinence may
lead to improved function even in the presence of
markedly depressed left ventricular ejection fraction'36'.
However, the strength of the study is the homogeneity of
the well investigated patient population, in which all
patients presented with overt congestive heart failure in
the documented absence of coronary artery disease or
any other form of secondary cardiomyopathy as well
as a complete follow-up over a period of 10 years. There
is only one previous study16' which compared the
long-term follow-up of such patients, and those
authors focused their attention mainly on patients with
idiopathic cardiomyopathy.
Clinical implications
Despite the above limitations, the present study indi-
cates that the long-term outcome of patients presenting
with severe congestive heart failure and left ventricular
dilatation due to alcoholic cardiomyopathy is more
favourable than that of patients with idiopathic cardio-
myopathy and similar degrees of heart failure and
left ventricular dilatation. This suggests that despite
structural changes inherent in marked left ventricular
dilation, disease progression is different in alcoholic
compared to idiopathic congestive cardiomyopathy.
Medical therapy and strong encouragement to avoid
alcohol are the treatment of choice for these patients,
and even in cases of documented alcohol abstinence the
indication for heart transplantation should be made
restrictively.
Addendum
After submission of the manuscript, a similar study
focusing on Indium-labelled monoclonal antimyosin
antibody imaging in patients with idiopathic and alco-
holic cardiomyopathy was published'371. In patients with
similar baseline values (ejection fraction of 29% in both
groups) to those of the present report, survival after
23 ± 16 months was better in 29 patients with alcoholic
as compared to 88 with idiopathic cardiomyopathy: 72%
vs 52% (P<005). Thus, our observations confirm these
results and extend them with our much longer follow-
up. The intensity of antibody uptake in the study by
Obrador et a/.'371 was found to be helpful for risk
stratification of patients with dilated cardiomyopathy.
In addition, these authors demonstrated parallel
improvements in antibody uptake and left ventricular
ejection fraction in a small subgroup of patients who
became abstinent.
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